Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk

Hypertension

Volumn 65, Issue 3, 2015, Pages 651-661

  Böhm, Michael ^a   Schumacher, Helmut ^b   Leong, Darryl ^c   Mancia, Giuseppe ^d   Unger, Thomas ^e   Schmieder, Roland ^f   Custodis, Florian ^a   Diener, Hans Christoph ^g   Laufs, Ulrich ^a   Lonn, Eva ^c   Sliwa, Karen ^h   Teo, Koon ^c   Fagard, Robert ⁱ   Redon, Josep ^j   Sleight, Peter ^k   Anderson, Craig ^l   O'Donnell, Martin ^m   Yusuf, Salim ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITY OF VALENCIA   (Spain)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^l ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^m NATIONAL UNIVERSITY OF IRELAND   (Ireland)

more..

Author keywords

heart rate; hypertension; myocardial infarction; stroke

Indexed keywords

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; ASIAN; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; COGNITION; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; COMPLICATION; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY;

ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TELMISARTAN;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84924275551     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04568     Document Type: Article

References (55)

1. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life.Neurology.2005;64:277-281. doi: 10.1212/01.WNL.0000149519.47454.F2.
2. Joas E, Bäckman K, Gustafson D, Ostling S, Waern M, Guo X, Skoog I. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years.Hypertension.2012;59:796-801. doi: 10.1161/HYPERTENSIONAHA.111.182204.
3. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials.Ann N Y Acad Sci.2010;1207:155-162. doi: 10.1111/j.1749-6632.2010.05726.x.
4. Gorelick PB, Scuteri A, Black SE, et al American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/ american stroke association. Stroke. 2011;42:2672-2713. doi: 10.1161/STR.0b013e3182299496.
5. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia.Ann Neurol.2007;61:403-410. doi: 10.1002/ana.21073.
6. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O'Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH; Syst-Eur investigators. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21:2251-2257. doi: 10.1097/01.hjh.0000098144.70956.0f.
7. Shimbo D, Newman JD, Aragaki AK, LaMonte MJ, Bavry AA, Allison M, Manson JE, Wassertheil-Smoller S. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension.2012;60:625-630. doi: 10.1161/HYPERTENSIONAHA.112.193094.
8. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).Eur Heart J. 2008;29:1327-1334. doi: 10.1093/eurheartj/ehn123.
9. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.Lancet.2008;372:817-821. doi: 10.1016/S0140-6736(08)61171-X.
10. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol.2011;100:11-19. doi: 10.1007/s00392-010-0207-x.
11. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet.2010;376:886-894. doi: 10.1016/S0140-6736(10)61259-7.
12. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation.2008;117:2377-2387. doi: 10.1161/CIRCULATIONAHA.107.746537.
13. Schirmer SH, Degen A, Baumhäkel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, Böhm M, Laufs U. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis.Eur Heart J.2012;33:1223-1231. doi: 10.1093/eurheartj/ehr255.
14. Custodis F, Gertz K, Balkaya M, Prinz V, Mathar I, Stamm C, Kronenberg G, Kazakov A, Freichel M, Böhm M, Endres M, Laufs U. Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice.Stroke.2011;42:1742-1749. doi: 10.1161/STROKEAHA.110.598607.
15. Böhm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke.Eur Heart J.2012;33:2804-2812. doi: 10.1093/eurheartj/ehs250.
16. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30:1556-1563. doi: 10.1097/HJH.0b013e3283552735.
17. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med.2008;358:1547-1559.
18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trial.Lancet.2008;372:1174-1183.
19. Hensel A, Luck T, Luppa M, Glaesmer H, Angermeyer MC, Riedel-Heller SG. Does a reliable decline in Mini Mental State Examination total score predict dementia? Diagnostic accuracy of two reliable change indices.Dement Geriatr Cogn Disord.2009;27:50-58. doi: 10.1159/000189267.
20. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, Koss E, Mohs R, Heyman A. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease.Arch Neurol.1999;56:857-862.
21. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
22. Hensel A, Angermeyer MC, Riedel-Heller SG. Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination.J Neurol Neurosurg Psychiatry.2007;78:1298-1303. doi: 10.1136/jnnp.2006.109074.
23. Schmand B, Lindeboom J, Launer L, Dinkgreve M, Hooijer C, Jonker C. What is a significant score change on the Mini-Mental State examination? Int J Geriatr Psychiatry. 1995;10:411-414.
24. Anderson C, Teo K, Gao P, et al ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.Lancet Neurol.2011;10:43-53. doi: 10.1016/S1474-4422(10)70250-7.
25. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551-561.
26. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A; Italian Longitudinal Study on Aging Working Group. Vascular risk factors, incidence of MCI, and rates of progression to dementia.Neurology.2004;63:1882-1891.
27. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline.N Engl J Med.2003;348:1215-1222. doi: 10.1056/NEJMoa022066.
28. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.BMJ.2001;322:1447-1451.
29. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease.Stroke.2004;35(11 Suppl 1):2620-2622. doi: 10.1161/01.STR.0000143318.70292.47.
30. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Havard University Press; 1996.
31. Snappin S, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier indicator. Am Stat. 2005;4:301-307.
32. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.J Hypertens. 2009;27:1360-1369. doi: 10.1097/HJH.0b013e32832d7370.
33. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension.Lancet.2010;375:938-948. doi: 10.1016/S0140-6736(10)60309-1.
34. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension.Lancet.2010;375:895-905. doi: 10.1016/S0140-6736(10)60308-X.
35. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994.Hypertension.2011;57:160-166. doi: 10.1161/HYPERTENSIONAHA.110.162255.
36. Liu W, Liu R, Sun W, Peng Q, Zhang W, Xu E, Cheng Y, Ding M, Li Y, Hong Z, Wu J, Zeng J, Yao C, Huang Y; CASISP Study Group. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions.Stroke.2012;43:2916-2922. doi: 10.1161/STROKEAHA.112.658369.
37. Birns J, Kalra L. Cognitive function and hypertension.J Hum Hypertens.2009;23:86-96. doi: 10.1038/jhh.2008.80.
38. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-1351.
39. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J; PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.Arch Intern Med.2003;163:1069-1075. doi: 10.1001/archinte.163.9.1069.
40. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, Greenlick MR, Hadley E, Moye L, Perry HM Jr. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med. 1994;154:2154-2160.
41. Prince MJ, Bird AS, Blizard RA, Mann AH. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults.BMJ.1996;312:801-805.
42. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.J Hypertens.2003;21:875-886. doi: 10.1097/01.hjh.0000059028.82022.89.
43. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial.Lancet Neurol.2008;7:683-689. doi: 10.1016/S1474-4422(08)70143-1.
44. Diener HC, Sacco RL, Yusuf S, et al Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.Lancet Neurol.2008;7:875-884. doi: 10.1016/S1474-4422(08)70198-4.
45. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis.Circulation.2012;126:569-578. doi: 10.1161/CIRCULATIONAHA.112.107565.
46. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.Lancet.2010;376:875-885. doi: 10.1016/S0140-6736(10)61198-1.
47. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate.J Am Coll Cardiol. 2010;56:1973-1983. doi: 10.1016/j.jacc.2010.09.014.
48. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation.2008;117:2377-2387. doi: 10.1161/CIRCULATIONAHA.107.746537.
49. Schirmer SH, Degen A, Baumhäkel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, Böhm M, Laufs U. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis.Eur Heart J.2012;33:1223-1231. doi: 10.1093/eurheartj/ehr255.
50. Baumhäkel M, Custodis F, Schlimmer N, Laufs U, Böhm M. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.Atherosclerosis.2010;212:55-62. doi: 10.1016/j.atherosclerosis.2010.03.002.
51. Kratz MT, Schumacher H, Sliwa K, Schmieder R, Pöss J, Mahfoud F, Unger T, Lonn E, Koon T, Mancia G, Sleight P, Yusuf S, Böhm M. Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.Eur J Prev Cardiol.2014;21:272-280. doi: 10.1177/2047487313494835.
52. Meel-van den Abeelen AS, Lagro J, Gommer ED, Reulen JP, Claassen JA. Baroreflex function is reduced in Alzheimer's disease: a candidate biomarker? Neurobiol Aging.2013;34:1170-1176. doi: 10.1016/j.neurobiolaging.2012.10.010.
53. van Beek AH, Sijbesma JC, Jansen RW, Rikkert MG, Claassen JA. Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use.J Alzheimers Dis.2010;21:519-526. doi: 10.3233/JAD-2010-100288.
54. Schoon Y, Lagro J, Verhoeven Y, Rikkert MO, Claassen J. Hypotensive syndromes are not associated with cognitive impairment in geriatric patients.Am J Alzheimers Dis Other Demen.2013;28:47-53. doi: 10.1177/1533317512466692.
55. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J, Yusuf S. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies.CMAJ.2012;184:E329-E336. doi: 10.1503/cmaj.111173.